## sanofi

## **2022 GRI Content Index**

Index to be read as a navigation tool to find the information in the relevant documents.

IR 2022 Integrated Report

URD 2022 Chapter 4 of the "Document d'Enregistrement Universel"

(Registration Document – audited by an independent third party)

20F 2022 Form 20-F

**CoC** Code of Conduct

**FCT** Factsheets in our <u>Document Center</u>

Email address

GRI STANDARDS SOURCE OMISSION

## **UNIVERSAL STANDARDS**

**GRI 1: FOUNDATION 2021** 

**GRI 2: GENERAL DISCLOSURES 2021** 

## 1. THE ORGANIZATION AND ITS REPORTING PRACTICES

IHE O	RGANIZATION AND ITS	KEPOKIJ	ING PRA	CTICES
2-1	Organizational details	Core	20F	P. 16 – Item 4 – Information on the Company
2-2	Entities included in the organization's sustainability reporting	Core	URD	P. 75 – Methodological note on data reporting
2-3	Reporting period, frequency and contact point	Core	URD	P. 75 – Methodological note on data reporting
2-4	Restatements of information	Core	URD	P. 75 – Methodological note on data reporting
2-5	External assurance	Core	URD	P. 80 – Report of the Independent Third Party
	2. /	ACTIVITI	ES AND	WORKERS
	Activities, value chain			P 17 - Item 4 - B/ Business

2-6	Activities, value chain and other business	Core	20F	P.17 - Item 4 - B/ Business	
2-0	relationships	Core	<b>2</b> 0F	overview	

2-7	Employees	Core	URD	P. 9 Building a clear vision of the workforce to support long term business success	
2-8	Workers who are not employees	Core	URD	P. 11 Building a clear vision of the workforce to support long term business success	
		3. GO	VERNA	NCE	
2-9	Governance structure and composition	Core	20F	P.83 – Item 6 – Directors, Senior Management and Employees	
	and composition		FCT	Corporate Governance and Compensation	
2-10	Nomination and selection of the highest governance body	Core	20F	P.83 – Item 6 – A/ Directors and Senior Management	
2-11	Chair of the highest governance body	Core	20F	P.83 – Item 6 – A/ Directors and Senior Management	
	Role of the highest		20F	P.141 – Item 6 – C/Board Practices: Appointments, Governance and CSR Committee	
2-12	governance body in overseeing the management of impacts	Core	URD	P.4 – 4.1.2. CSR Governance	
			FCT	P.6 - <u>CSR Materiality</u> , <u>Strategy</u> <u>&amp; Governance</u> : CSR Governance	
2-13	Delegation of responsibility for managing impacts	Core	URD	P.4 – 4.1.2. CSR Governance	
2-14	Role of the highest governance body in sustainability reporting	Core	20F	P.141 – Item 6 – C/Board Practices: Appointments, Governance and CSR Committee	
2-15	Conflicts of interest	Core	20F	P. 171 - Item 16G. Corporate Governance	
2-16	Communication of critical concerns	Core	FCT	<u>Vigilance Plan</u>	
2-17	Collective knowledge of the highest governance body	Core	20F	P.89 – Item 6 –A/Directors and Senior Management: Competencies of Board members	

sanofi

•					
2-18	Evaluation of the performance of the highest governance body	Core	20F	P.87 – Item 6 –A/Directors and Senior Management: Board evaluation	
2-19	Renumeration policies	Core	20F	P.113 – Item 6 – B/Compensation	
2-20	Process to determine remuneration	Core	20F	P.113 – Item 6 – B/Compensation	
2-21	Annual total compensation ratio	Core	20F	P.129 – Item 6 – B/Compensation: Pay Ratio	
	4. STRATI	EGY, POL	ICIES A	IND PRACTICES	
2-22	Statement on sustainable development strategy	Core	URD	P.3 – Section 4.1. CSR strategy and governance	
2-23	Policy commitments	Core	FCT	P.3-6 - <u>Ethics &amp; Business</u> <u>Integrity</u>	
2-24	Embedding policy	Core	FCT	Global Quality Policy	
	commitments		FCT	P.3-8 - <u>Lobbying</u>	
2-25	Processes to remediate negative impacts	Core	URD	P. 56 – Section 4.4. Vigilance plan	
	negative impacts		FCT	<u>Vigilance Plan</u>	
2-26	Mechanisms for seeking advice and raising concerns	Core	URD	P. 40 - 4.3.8.2.3. Whistle- blowing	
2-27	Compliance with laws and regulations	Core	URD	P.42 - Section 4.3.8. Ethics and business integrity	
			FCT	P.3-8 - <u>Lobbying</u>	
2-28	Membership associations	Core	FCT	Patient Associations Supported by Sanofi	
	5. STAKE	HOLDER	ENGAG	EMENT	
2-29	Approach to stakeholder engagement	Core	URD	P.42 - Section 4.3.8. Ethics and business integrity	
			FCT	P.3-6 - <u>Ethics &amp; Business</u> <u>Integrity</u>	
2-30	Collective bargaining agreements	Core	URD	P. 15 – Section 4.3.1.4.3. Fostering dialogue to pursue progress	

sanofi

GRI 3: M	ATERIAL TOPICS 2021			
3-1	Process to determine material topics	Material	FCT	Sanofi's CSR, Materiality, Strategy & Governance: Double Materiality
3-2	List of material topics	Material	URD	A table of all material topics considered as risks is presented in P.5 - Section 4.2.2. Table of SEFP risks and issues  The risks are developed in P.6-56 - Section 4.3. Detailed description of SEFP issues and risks  P.1-98 - All our material topics are included in the Chapter 4 of
3-3	Management of material topics	Material	URD	the "Document d'Enregistrement Universel" in which policies, commitment, goals, targets, responsibilities, resources, grievance mechanisms and specific actions are described. This report is audited by an independent third party.
	TOPIC-SPECI	FIC STAN	IDARDS	- MATERIAL TOPICS
		EC	ONOMI	С
	GRI 203: II	NDIRECT	ECONO	MIC IMPACTS 2016
			IR	P.24 - Improving People's Lives
203-1	Infrastructure investments and	Material	20F	P.54 - Item 4 - D/ Property, plant and equipment
	services supported		URD	P.22 - Section 4.3.2. Access to healthcare
	GRI 2	205: ANT	I-CORR	UPTION 2016
			URD	P.38 - Section 4.3.8. Ethics and business integrity
205-1	Operations assessed for risks related to	Material	20F	P.1 - Item 3 - D. Risk factors - Risks relating to legal and regulatory matters
203-1	corruption		FCT	P.7 - <u>Ethics and Business</u> <u>Integrity</u>

			FCT	P.1-7 - Anti-Bribery Policy	
205-2	Communication and training about anti-	Material	FCT	P.9-10 - Ethics and Business Integrity	
	corruption policies and procedures		URD	P.38 - Section 4.3.8. Ethics and business integrity	
205-3	Confirmed incidents of corruption and actions taken	Material	20F	P.151 - Item 8 - Financial Information - Information on Legal or Arbitration Proceedings	
		ENVIF	RONME	NTAL	
		GRI 302	: ENER	GY 2016	
			URD	P.46 - Section 4.3.10.2.1. Energy	
302-1	Energy consumption	Material	FCT	ESG Key Performance Indicators	
	within the organization		FCT	P.3 - Climate Change –	
				Road to Net Zero	
202.4		Material	URD	P.46 - Section 4.3.10.2.1. Energy	
302-4	Reduction of energy consumption		FCT	ESG Key Performance Indicators	
302-5	Reductions in energy	Material	FCT	P.3 - Transporting Medicines and Vaccines	
<b>J J J</b>	requirements of products and services		FCT	P.3-5 - <u>Eco-Design</u>	
		GRI 303	: WATE	R 2018	
303-1	Interactions with water as a shared resource	Material	FCT	P.4 - <u>Water Stewardship</u>	
303-2	Management of water discharge-related impacts	Material	FCT	P.6-7 - <u>Water Stewardship</u>	
			URD	P.49 - Section 4.3.10.3.2. Water consumption	
303-3	Water withdrawal	Material	FCT	ESG Key Performance Indicators	
			FCT	P.3-10 - Water Stewardship	

303-4	Water discharge	Material	URD	P.52 - Section 4.3.10.8 Environmental releases	
303-5	Water consumption	Material	URD	P. 49 - Section 4.3.10.3.2. Water consumption	
	GR	I 304: B1	ODIVE	RSITY 2016	
304-1	Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas	Material	FCT	P.5 - <u>Biodiversity</u>	
304-2	Significant impacts of activities, products and services on biodiversity		FCT	P.6- 8 - <u>Biodiversity</u>	
	G	RI 305:	EMISSI	ONS 2016	
305-1	Direct (Scope 1) GHG emissions	Material	URD	P.46 - 47 - Section 4.3.10.2.2.1. Direct and indirect emissions: Scopes 1 & 2	
305-2	Energy indirect (Scope 2) GHG emissions	Material	URD FCT	P.46 - 47 - Section 4.3.10.2.2.1. Direct and indirect emissions: Scopes 1 & 2 P.6-7 - Climate Change -	
			FCT	Road to Net Zero  ESG Key Performance Indicators	
305-3	Other indirect (Scope 3)	Material	URD	P.47 - Section 4.3.10.2.2.2. Other indirect emissions: Scope 3	
	GHG emissions	Material	FCT	P.6-7 - <u>Climate Change -</u> Road to Net Zero	
			FCT	ESG Key Performance Indicators	
305-5	Reduction of GHG emissions	Material	URD	P.41 - Section 4.3.10.1. The Planet Care roadmap	
			FCT	P.3 - Transporting medicines and vaccines	

305-7	Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions	Material	URD	P.54 - Section 4.3.10.8.4.3. Managing air emissions: optimizing the use of solvents and control over volatile organic compound emissions  ESG Key Performance Indicators	
			FCT	P.3-5 - <u>Protection</u> of the <u>Atmosphere</u>	
GRI 306:	<b>EFFLUENTS AND WAST</b>	E 2016			
			URD	P.50 - Section 4.3.10.4.1. Waste generated	
306-2	Waste by type and disposal method	Material	FCT	P.3-4 - <u>Circular Economy &amp;</u> Waste Management	
			FCT	ESG Key Performance Indicators	
GRI 308:	SUPPLIER ENVIRONME	NTAL AS	SESSMI	ENT 2016	
308-1	New suppliers that were screened using environmental criteria	Material	FCT	P.27 - <u>Vigilance Plan</u>	
	Negative environmental		URD	P.56 - Section 4.4.1. Methodology for selecting risks for the duty of vigilance	
308-2	impacts in the supply chain and actions taken	Material	FCT	P.25-29 - <u>Vigilance Plan</u>	
			FCT	P.4-13 - <u>Sustainable</u> <u>Procurement</u>	
		S	OCIAL		
	GR	RI 401: EI	MPLOYI	MENT 2016	
401-1	New employee hires and employee turnover	Material	URD	P.10 - Section 4.3.1.2. Building a clear vision of the workforce to support long term business success	
401-3	Parental leave	Material	URD	P.21 - Section 4.3.1.5.3.3. Global gender-neutral paid parental leave policy	
	GRI 403: OCCU	JPATION.	AL HEA	LTH AND SAFETY 2018	

	Occupational health and safety		URD	P.60 - Section 4.4.7. Employee health and safety
403-1	management system	Material	FCT	P.3-5 - <u>Health and Safety in</u> the Workplace
403-2	Hazard identification, risk assessment, and incident investigation	Material	URD	P.62 - Section 4.4.7.2. Workplace health and safety programs
			FCT	ESG Key Performance Indicators
403-5	Worker training on occupational health and safety	Material	FCT	P.3-5 - <u>Health and Safety in</u> the Workplace
403-6	Promotion of worker health	Material	URD	P.62 – Section 4.4.7.2 Workplace health and safety programs
403-8	Workers covered by an occupational health and safety management system	Material	URD	P.62 – Section 4.4.7.2 Workplace health and safety programs
403-9	Work-related injuries	Material	URD	P.63 – Section 4.4.7.3 Occupational injury/disease indicators
403-10	Work-related ill health	Material	URD	P.63 - Section 4.4.7.3 Occupational injury/disease indicators
	GRI 404:	TRAININ	G AND	EDUCATION 2016
	Average hours of training per year per employee	Material	URD	P.13 – Section 4.3.1.3.2.3. A broad learning offer through Sanofi University
	Programs for upgrading employee skills and transition assistance programs	Material	URD	P.13 – Section 4.3.1.3.2.3. A broad learning offer through Sanofi University
	GRI 405: DIVE	RSITY AN	ID EQU	AL OPPORTUNITY 2016

405-1 405-2 GRI 407:	Diversity of governance bodies and employees  Ratio of basic salary and renumeration of women to men  FREEDOM OF ASSOCIA	Material	UKD	P. 83 – Item 6 - Directors, Senior Management and Employees - Board of Directors  P.33 - Building representative leadership  P.2-9 - Corporate Governance and compensation  P.17 - Section 4.3.1.5. Creating our Diversity Edge  P. 19 – Section 4.3.1.5.2.1. Focus on gender balance  ECTIVE BARGAINING 2016  P.58 - Section 4.4.6.
407-1	Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	Material	FCT FCT	Fundamental human rights at work and P.65 - 4.4.14. Procurement and subcontracting P.4 - Fundamental Human Rights at Work  P.5-6 - Sustainable Procurement
GRI 408:	CHILD LABOR 2016			
408-1	Operations and suppliers at significant risk for incidents of child labor	Material	FCT	P.6-7 - <u>Children's Rights</u>
GRI 409:	FORCED OR COMPULSO	DRY LABO	R 2016	
409-1	Operations and suppliers at significant risk for incidents of forced or compulsory labor	Material	URD FCT	P.58 - Section 4.4.6. Fundamental human rights at Work  P.1-13 - Human Rights Due Diligence
			FCT	P.5 - Fundamental Human Rights at Work

GRI 413:	LOCAL COMMUNITIES	2016				
	Operations with local community		FCT	P.1-7 – <u>Employee</u> Engagement on Environment		
413-1	engagement, impact assessments, and development programs	Material	FCT	P.1-8 - <u>Employee</u> <u>Volunteering</u>		
440.0	Operations with significant actual and	Material	URD	P.52 - Section 4.3.10.8. Environmental releases		
413-2	potential negative impacts on local communities		20F	P.13 - Item 3 - D. Risk Factors - Environmental and safety risks of our industrial activities		
GRI 414:	SUPPLIER SOCIAL ASS	ESSMENT	2016			
414-1	New suppliers that were screened using social criteria	Material	FCT	P.6 - <u>Sustainable Procurement</u>		
414-2	Negative social impacts in the supply chain and actions taken	Material	URD	P.65 – Section 4.4.14. Procurement and subcontracting		
GRI 416: CUSTOMER HEALTH AND SAFETY 2016						
GRI 416:	CUSTOMER HEALTH AN	ID SAFET	Y 2016			
GRI 416:	CUSTOMER HEALTH AN	ID SAFET	Y 2016 URD	P.60 - Section 4.4.7. Employee health and safety		
GRI 416:	CUSTOMER HEALTH AN	ID SAFET				
	Assessment of the	ID SAFET	URD	Employee health and safety  P.4-9 - Medical Ethics and		
GRI 416: 416-1		I <b>D SAFET</b> Material	URD FCT	P.4-9 - Medical Ethics and Bioethics and Clinical Trials  P.3-4 - Implementation of		
	Assessment of the health and safety impacts of product and		URD  FCT  FCT	P.4-9 - Medical Ethics and Bioethics and Clinical Trials  P.3-4 - Implementation of REACH regulation  P.1-5 - Quality Management		
	Assessment of the health and safety impacts of product and		FCT FCT	P.4-9 - Medical Ethics and Bioethics and Clinical Trials  P.3-4 - Implementation of REACH regulation  P.1-5 - Quality Management System  P.3 - Serialization: Medicine Identification, Authentication		